SCHEMBL891708

SCHEMBL891708

O=C(O)C=CC=CC(=O)OCl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.42
TP53 P04637 1/20 0.42
EGLN1 Q9GZT9 1/20 0.42
EGLN3 Q9H6Z9 1/20 0.42
HCAR2 Q8TDS4 6/20 0.40
ALDH1A1 P00352 3/20 0.38
ALOX15 P16050 2/20 0.38
RECQL P46063 2/20 0.38
HSD17B10 Q99714 2/20 0.38
PPARA Q07869 1/20 0.33
TDP1 Q9NUW8 3/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
ACHE P22303 1/20 0.32
BACE1 P56817 1/20 0.32
MASP2 O00187 1/20 0.32
F2 P00734 1/20 0.32
GABRR1 P24046 2/20 0.31
GABRR2 P28476 2/20 0.31
BLM P54132 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19625968 0.91 HCAR2 (0.33) TSHRTP53EGLN1EGLN3HCAR2
SCHEMBL10589658 0.91 HCAR2 (0.33) TSHRTP53EGLN1EGLN3HCAR2
SCHEMBL10444879 0.82
SCHEMBL10444881 0.82
SCHEMBL26197211 0.82
SCHEMBL16504472 0.80 TSHR (0.44) TSHRTP53EGLN1EGLN3HCAR2
SCHEMBL4492285 0.79
SCHEMBL10444878 0.78 HCAR2 (0.44) TSHRTP53EGLN1EGLN3HCAR2
SCHEMBL1249383 0.78 HCAR2 (0.44) TSHRTP53EGLN1EGLN3HCAR2
SCHEMBL30694696 0.78 TSHR (0.67) TSHRTP53EGLN1EGLN3HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10329575-B2 Regulatory sequence for plants CERES, INC. (US) 2019-06-25 US disclosed
US-20180223303-A1 SEQUENCE-DETERMINED DNA FRAGMENTS AND CORRESPONDING POLYPEPTIDES ENCODED THEREBY CERES INC (US) 2018-08-09 US disclosed
US-20170037426-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby ALEXANDROV NICKOLAI (US) 2017-02-09 US disclosed
US-20160076046-A1 PROMOTER, PROMOTER CONTROL ELEMENTS, AND COMBINATIONS, AND USES THEREOF CERES, INC. (US) 2016-03-17 US disclosed
US-9029523-B2 Promoter, promoter control elements, and combinations, and uses thereof CERES, INC. (US) 2015-05-12 US disclosed
US-20150033417-A9 Promoter, promoter control elements, and combinations, and uses thereof ALEXANDROV NICKOLAI (US) 2015-01-29 US disclosed
US-8877916-B2 Promoter, promoter control elements, and combinations, and uses thereof CERES, INC. (US) 2014-11-04 US disclosed
US-20120159672-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby CERES, INC. 2012-06-21 US disclosed
US-20120084885-A1 Promoter, promoter control elements, and combinations, and uses thereof ALEXANDROV NICKOLAI (US) 2012-04-05 US disclosed
US-20110191912-A1 Promoter, promoter control elements, and combinations, and uses thereof ALEXANDROV NICKOLAI 2011-08-04 US disclosed
US-20100037355-A1 SEQUENCE-DETERMINED DNA FRAGMENTS AND CORRESPONDING POLYPEPTIDES ENCODED THEREBY CERES, INC (US) 2010-02-11 US disclosed
US-20090265815-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded therapy ALEXANDROV NICKOLAI 2009-10-22 US disclosed
US-20070214517-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby CERES, INC. (US) 2007-09-13 US disclosed
US-20060150283-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby ALEXANDROV NICKOLAI 2006-07-06 US disclosed
US-20060048240-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby ALEXANDROV NICKOLAI 2006-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037426-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby RNGTT, CPSF1, CPSF6 TSHR 1630/4885TP53 676/4885EGLN1 4292/4885
US-20150033417-A9 Promoter, promoter control elements, and combinations, and uses thereof RNGTT, GTF3C5, GTF3C1 TSHR 1612/4885TP53 871/4885EGLN1 3371/4885
US-20120084885-A1 Promoter, promoter control elements, and combinations, and uses thereof RNGTT, GTF3C5, GTF3C1 TSHR 1608/4885TP53 846/4885EGLN1 3352/4885
US-20070214517-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby RNGTT, CPSF1, CPSF6 TSHR 1630/4885TP53 676/4885EGLN1 4292/4885
US-20110191912-A1 Promoter, promoter control elements, and combinations, and uses thereof RNGTT, GTF3C5, GTF3C1 TSHR 1612/4885TP53 871/4885EGLN1 3371/4885
US-20120159672-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby RNGTT, CPSF1, CPSF6 TSHR 1630/4885TP53 676/4885EGLN1 4292/4885
US-20100037355-A1 SEQUENCE-DETERMINED DNA FRAGMENTS AND CORRESPONDING POLYPEPTIDES ENCODED THEREBY RNGTT, CPSF1, CPSF6 TSHR 1630/4885TP53 676/4885EGLN1 4292/4885
US-20060048240-A1 Sequence-determined DNA fragments and corresponding polypeptides encoded thereby RNGTT, CPSF1, CPSF6 TSHR 1630/4885TP53 676/4885EGLN1 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.